The emergence of dual-action receptor agonists in the treatment of type 2 diabetes and obesity has sparked considerable attention, particularly regarding retatrutide and tirzepatide. While both medications target both https://amiexkrf807383.win-blog.com/19840955/retatrutide-vs-tirzepatide-a-comparative-analysis